



Advancing Research. Improving Lives.™

Scientific Session Workshop Agenda

Date: Friday, July 11, 2014
Start and End Time: 8:00 am – 10:00 am
Co-Chairs: Norman Wolmark, MD; Walter J. Curran, Jr., MD; Philip J. DiSaia, MD

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss the results of recently reported trials for low-grade glioma, non-small cell lung cancer, and cervical cancer and their implications for treatment strategies.
2. Identify the risk factors for gastrointestinal adverse events when treating with bevacizumab for patients with advanced ovarian cancer.
3. Describe the role of Tadalafil in the prevention of erectile dysfunction after radiotherapy for prostate cancer
4. Identify the role of racial genetic admixture in endometrial cancer treatment
5. Identify patients that may be candidates for current trials using molecular profiles for treatment assignment.

WORKSHOP AGENDA

8:00 – 8:10 am	Introduction and Welcome	
8:10 – 8:20 am	RTOG 9802: Phase III Study of Radiation Therapy (RT) with or without Procarbazine, CCNU, and Vincristine (PCV) in Low-Grade Glioma	Jan C. Buckner, MD
8:20 – 8:30 am	Discussant for RTOG 9802	Walter J. Curran, Jr., MD
8:30 – 8:40 am	RTOG 0831: Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer	Thomas M. Pisansky, MD
8:40 – 8:50 am	RTOG 0617: The Effect of Institutional Clinical Trial Enrollment Volume on Survival of Patients with Stage III Non-Small Cell Lung Cancer Treated with Chemoradiation	Bree Ruppert Eaton, MD
8:50 – 9:00 am	GOG 0218: Risk factors for gastrointestinal adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer	Robert A. Burger, MD
9:00 – 9:10 am	GOG 8022: The role of racial genetic admixture with endometrial cancer outcomes	Rodney P. Rocconi, MD
9:10 – 9:20 am	GOG 0219: A phase III randomized trial of weekly cisplatin and radiation versus cisplatin and tirapazamine and radiation in stage IB2,	Paul DiSilvestro,, MD

IIA, IIB, IIIB and IVA cervical carcinoma limited to the pelvis

9:20 – 9:30 am	Discussant for GYN trials	Robert S. Mannel, MD
9:30 – 9:45 am	NSABP B-55/BIG 6-13 (OLYMPIA): A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy	Charles Geyer, Jr., MD Priya Rastogi, MD
9:45 – 10:00 am	Molecular Analysis for Therapy Choice (NCI-MATCH)	Barbara A. Conley, MD Cancer Diagnosis Program NCI